BR108
/ Zhejiang Hisun Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 30, 2023
A Phase I Study of BR108 in Hematological Malignancies
(clinicaltrials.gov)
- P1 | N=180 | Recruiting | Sponsor: Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
New P1 trial • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology
1 to 1
Of
1
Go to page
1